{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=X-Linked+Severe+Combined+Immunodeficiency",
    "query": {
      "condition": "X-Linked Severe Combined Immunodeficiency"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=X-Linked+Severe+Combined+Immunodeficiency&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T04:01:08.697Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00490100",
      "title": "Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Growth Failure",
        "X-linked Severe Combined Immunodeficiency (XSCID)",
        "Growth Hormone Resistence"
      ],
      "interventions": [
        {
          "name": "Increlex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 6,
      "start_date": "2007-06",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2015-07-03",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00490100"
    },
    {
      "nct_id": "NCT00128973",
      "title": "Evaluation of Patients With Immune Function Abnormalities",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Granulomatous Disease (CGD)",
        "X-Linked Severe Combined Immune Deficiency (XSCID)",
        "Leukocyte Adhesion Deficiency 1 (LAD)",
        "Graft Versus Host Disease (cGvHD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3500,
      "start_date": "2005-09-19",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128973"
    },
    {
      "nct_id": "NCT00744692",
      "title": "Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Malignant Disorders",
        "Immunodeficiencies",
        "Congenital Marrow Failures",
        "Hemoglobinopathies",
        "Inborn Errors of Metabolism",
        "Sickle Cell",
        "Thalassemia",
        "Lysosomal Storage Disease"
      ],
      "interventions": [
        {
          "name": "Unrelated Umbilical Cord Blood Transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reduced Intensity Conditioning",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-10",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2014-08-13",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00744692"
    },
    {
      "nct_id": "NCT01962415",
      "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions",
        "Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "Juvenile Rheumatoid Arthritis (JRA)"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "2 Months to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-02-04",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962415"
    },
    {
      "nct_id": "NCT01346150",
      "title": "Patients Treated for SCID (1968-Present)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SCID",
        "ADA-SCID",
        "XSCID",
        "Leaky SCID",
        "Omenn Syndrome",
        "Reticular Dysgenesis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1007,
      "start_date": "2011-05-15",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01346150"
    },
    {
      "nct_id": "NCT01129544",
      "title": "Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Gene transfer",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "David Williams",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 8,
      "start_date": "2010-04",
      "completion_date": "2023-03",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129544"
    },
    {
      "nct_id": "NCT00028236",
      "title": "Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Gene-Transduced Autologous CD34+ Stem Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "18 Months to 20 Years"
      },
      "enrollment_count": 3,
      "start_date": "2001-12-10",
      "completion_date": "2011-07-25",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028236"
    },
    {
      "nct_id": "NCT00220766",
      "title": "Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunologic Deficiency Syndrome",
        "Agammaglobulinemia",
        "Severe Combined Immunodeficiency",
        "Wiskott-Aldrich Syndrome",
        "Common Variable Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        },
        {
          "name": "Dextrose, 5% in Water",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2002-08",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2009-09-25",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220766"
    },
    {
      "nct_id": "NCT03311503",
      "title": "Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency, X Linked",
        "Gene Therapy"
      ],
      "interventions": [
        {
          "name": "autologous CD34+ cell transduced with G2SCID vector",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "David Williams",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "0 Years to 5 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2018-02-26",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311503"
    },
    {
      "nct_id": "NCT02231710",
      "title": "Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Immune Deficiency Disorders",
        "Hemophagocytic Lymphohistiocytosis",
        "Inherited Bone Marrow Failure Syndrome",
        "Hemoglobinopathies",
        "Metabolic Disorders"
      ],
      "interventions": [
        {
          "name": "BPX-501 and Rimiducid",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "4 Months to 55 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-02",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-06-10T04:01:08.697Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02231710"
    }
  ]
}